Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,32778548,maximum tolerated dose (MTD),"An acute-dose study yielded a maximum tolerated dose (MTD) of 1,500 mg/kg, 227-fold higher than the fully curative dose.",Discovery and Preclinical Development of Antigiardiasis Fumagillol Derivatives. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32778548/),[mg] / [kg],"1,500",36913,DB02640,Fumagillin
,15029870,T(1/2)beta,The blood level following the intravenous route declined in first-order kinetics with T(1/2)beta values of 0.72 to approximately 0.78 h for CKD-732 and 0.92 to approximately 1.09 h for M11 in rats at a dose of 7.5 to approximately 30 mg/kg.,"Absorption, distribution, metabolism, and excretion of CKD-732, a novel antiangiogenic fumagillin derivative, in rats, mice, and dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15029870/),h,0.72 to,38717,DB02640,Fumagillin
,15029870,T(1/2)beta,The blood level following the intravenous route declined in first-order kinetics with T(1/2)beta values of 0.72 to approximately 0.78 h for CKD-732 and 0.92 to approximately 1.09 h for M11 in rats at a dose of 7.5 to approximately 30 mg/kg.,"Absorption, distribution, metabolism, and excretion of CKD-732, a novel antiangiogenic fumagillin derivative, in rats, mice, and dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15029870/),h,0.92 to,38718,DB02640,Fumagillin
,15029870,T(1/2)beta,"In dogs, T(1/2)beta values of CKD-732 and M11 were 1.54 and 1.79 h, respectively.","Absorption, distribution, metabolism, and excretion of CKD-732, a novel antiangiogenic fumagillin derivative, in rats, mice, and dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15029870/),h,1.54,38719,DB02640,Fumagillin
,15029870,T(1/2)beta,"In dogs, T(1/2)beta values of CKD-732 and M11 were 1.54 and 1.79 h, respectively.","Absorption, distribution, metabolism, and excretion of CKD-732, a novel antiangiogenic fumagillin derivative, in rats, mice, and dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15029870/),h,1.79,38720,DB02640,Fumagillin
,15029870,total amount excreted,"The total amount excreted in urine, bile, and feces was 2.13% for CKD-732 and 1.29% for M11 in rats, and 1.58% for CKD-732 and 2.28% for M11 in dogs.","Absorption, distribution, metabolism, and excretion of CKD-732, a novel antiangiogenic fumagillin derivative, in rats, mice, and dogs. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15029870/),%,2.13,38721,DB02640,Fumagillin
,15029870,total amount excreted,"The total amount excreted in urine, bile, and feces was 2.13% for CKD-732 and 1.29% for M11 in rats, and 1.58% for CKD-732 and 2.28% for M11 in dogs.","Absorption, distribution, metabolism, and excretion of CKD-732, a novel antiangiogenic fumagillin derivative, in rats, mice, and dogs. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15029870/),%,1.29,38722,DB02640,Fumagillin
,15029870,total amount excreted,"The total amount excreted in urine, bile, and feces was 2.13% for CKD-732 and 1.29% for M11 in rats, and 1.58% for CKD-732 and 2.28% for M11 in dogs.","Absorption, distribution, metabolism, and excretion of CKD-732, a novel antiangiogenic fumagillin derivative, in rats, mice, and dogs. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15029870/),%,1.58,38723,DB02640,Fumagillin
,15029870,total amount excreted,"The total amount excreted in urine, bile, and feces was 2.13% for CKD-732 and 1.29% for M11 in rats, and 1.58% for CKD-732 and 2.28% for M11 in dogs.","Absorption, distribution, metabolism, and excretion of CKD-732, a novel antiangiogenic fumagillin derivative, in rats, mice, and dogs. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15029870/),%,2.28,38724,DB02640,Fumagillin
,19218530,T(max),"Pharmacokinetic analysis after a single p.o. dose showed a rapid T(max) value of 15 min followed by biphasic elimination (t(1/2), approximately 20 min and t(1/2), approximately 5 h) and an estimated oral bioavailability of approximately 15%.","Involution of collagen-induced arthritis with an angiogenesis inhibitor, PPI-2458. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19218530/),min,15,87399,DB02640,Fumagillin
,19218530,t(1/2),"Pharmacokinetic analysis after a single p.o. dose showed a rapid T(max) value of 15 min followed by biphasic elimination (t(1/2), approximately 20 min and t(1/2), approximately 5 h) and an estimated oral bioavailability of approximately 15%.","Involution of collagen-induced arthritis with an angiogenesis inhibitor, PPI-2458. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19218530/),min,20,87400,DB02640,Fumagillin
,19218530,t(1/2),"Pharmacokinetic analysis after a single p.o. dose showed a rapid T(max) value of 15 min followed by biphasic elimination (t(1/2), approximately 20 min and t(1/2), approximately 5 h) and an estimated oral bioavailability of approximately 15%.","Involution of collagen-induced arthritis with an angiogenesis inhibitor, PPI-2458. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19218530/),h,5,87401,DB02640,Fumagillin
,19218530,oral bioavailability,"Pharmacokinetic analysis after a single p.o. dose showed a rapid T(max) value of 15 min followed by biphasic elimination (t(1/2), approximately 20 min and t(1/2), approximately 5 h) and an estimated oral bioavailability of approximately 15%.","Involution of collagen-induced arthritis with an angiogenesis inhibitor, PPI-2458. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19218530/),%,15,87402,DB02640,Fumagillin
,9552050,Elimination half-life,"Elimination half-life values were short (range, 0.01 to 0.61 hours).",Fumagillin analog in the treatment of Kaposi's sarcoma: a phase I AIDS Clinical Trial Group study. AIDS Clinical Trial Group No. 215 Team. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9552050/),h,0.01 to 0.61,189343,DB02640,Fumagillin
,9552050,time to partial response,"The median time to partial response was 4 weeks (range, 2 to 25), and the median duration of response was 11 weeks (range, 3 to 26+).",Fumagillin analog in the treatment of Kaposi's sarcoma: a phase I AIDS Clinical Trial Group study. AIDS Clinical Trial Group No. 215 Team. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9552050/),weeks,4,189344,DB02640,Fumagillin
,9552050,duration of response,"The median time to partial response was 4 weeks (range, 2 to 25), and the median duration of response was 11 weeks (range, 3 to 26+).",Fumagillin analog in the treatment of Kaposi's sarcoma: a phase I AIDS Clinical Trial Group study. AIDS Clinical Trial Group No. 215 Team. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9552050/),weeks,11,189345,DB02640,Fumagillin
,9017768,Cmax,The Cmax ranged between 6.6 ng/ml at the lowest dosage (4.6 mg/m2) and 597.1 ng/ml at the highest dosage (43.1 mg/m2).,"The pharmacokinetics of TNP-470, a new angiogenesis inhibitor. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9017768/),[ng] / [ml],6.6,240041,DB02640,Fumagillin
,9017768,Cmax,The Cmax ranged between 6.6 ng/ml at the lowest dosage (4.6 mg/m2) and 597.1 ng/ml at the highest dosage (43.1 mg/m2).,"The pharmacokinetics of TNP-470, a new angiogenesis inhibitor. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9017768/),[ng] / [ml],597.1,240042,DB02640,Fumagillin
,9017768,terminal half-life,"The agent was rapidly cleared from the circulation with a short terminal half-life (0.88 +/- 2.5 hr), which is consistent with preclinical data.","The pharmacokinetics of TNP-470, a new angiogenesis inhibitor. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9017768/),h,0.88,240043,DB02640,Fumagillin
,9017768,Peak plasma concentrations,"Peak plasma concentrations of AGM-1883, an active metabolite, ranged between 0.4 and 158.1 ng/ml.","The pharmacokinetics of TNP-470, a new angiogenesis inhibitor. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9017768/),[ng] / [ml],0.4 and 158.1,240044,DB02640,Fumagillin
